A Cluster of Proteins Implicated in Kidney Disease Is Increased in High-Density Lipoprotein Isolated from Hemodialysis Subjects

Journal of Proteome Research

Volumn 14, Issue 7, 2015, Pages 2792-2806

  Shao, Baohai ^a   De Boer, Ian ^a   Tang, Chongren ^a   Mayer, Philip S ^a   Zelnick, Leila ^a   Afkarian, Maryam ^a   Heinecke, Jay W ^a   Himmelfarb, Jonathan ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

cardiovascular diseases; end stage renal disease; hemodialysis; high density lipoprotein; mass spectrometry; proteomics; selected reaction monitoring; shotgun proteomics

Indexed keywords

HIGH DENSITY LIPOPROTEIN; CST3 PROTEIN, HUMAN; CYSTATIN C;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; END STAGE RENAL DISEASE; FEMALE; HEMODIALYSIS PATIENT; HUMAN; ISOTOPE DILUTION ASSAY; KIDNEY DISEASE; MALE; MASS SPECTROMETRY; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ISOLATION; PROTEOMICS; AMINO ACID SEQUENCE; BLOOD; CHEMISTRY; HEMODIALYSIS; KIDNEY FAILURE, CHRONIC; MOLECULAR GENETICS;

ADULT; AMINO ACID SEQUENCE; CYSTATIN C; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; RENAL DIALYSIS;

EID: 84947213636     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/acs.jproteome.5b00060     Document Type: Article

References (74)

1. Go, A. S.; Chertow, G. M.; Fan, D.; McCulloch, C. E.; Hsu, C. Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N. Engl. J. Med. 2004, 351, 1296-1305
2. Himmelfarb, J.; Stenvinkel, P.; Ikizler, T. A.; Hakim, R. M. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia Kidney Int. 2002, 62, 1524-1538
3. Goodkin, D. A.; Bragg-Gresham, J. L.; Koenig, K. G.; Wolfe, R. A.; Akiba, T.; Andreucci, V. E.; Saito, A.; Rayner, H. C.; Kurokawa, K.; Port, F. K.; Held, P. J.; Young, E. W. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS) J. Am. Soc. Nephrol. 2003, 14, 3270-3277
4. Gomez, R. A. Renal disease in Colombia Renal Failure 2006, 28, 643-647
5. Bakris, G.; Vassalotti, J.; Ritz, E.; Wanner, C.; Stergiou, G.; Molitch, M.; Nesto, R.; Kaysen, G. A.; Sowers, J. R. National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events Kidney Int. 2010, 78, 726-736
6. Shah, S.; Paparello, J.; Danesh, F. R. Effects of statin therapy on the progression of chronic kidney disease Adv. Chronic Kidney Dis. 2005, 12, 187-195
7. Rabb, H. Does statin pretreatment reduce the risk of contrast-induced nephropathy? Nat. Clin. Pract. Nephrol. 2006, 2, 124-5
8. Gordon, D. J.; Rifkind, B. M. High-density lipoprotein - the clinical implications of recent studies N. Engl. J. Med. 1989, 321, 1311-1316
9. Davidson, W. S.; Thompson, T. B. The structure of apolipoprotein A-I in high density lipoproteins J. Biol. Chem. 2007, 282, 22249-22253
10. Oram, J. F.; Heinecke, J. W. ATP-binding cassette transporter A1: A cell cholesterol exporter that protects against cardiovascular disease Physiol. Rev. 2005, 85, 1343-1372
11. Thomas, M. J.; Bhat, S.; Sorci-Thomas, M. G. Three-dimensional models of HDL apoA-I: implications for its assembly and function J. Lipid Res. 2008, 49, 1875-1883
12. Lee, J. Y.; Parks, J. S. ATP-binding cassette transporter AI and its role in HDL formation Curr. Opin Lipidol. 2005, 16, 19-25
13. Haas, M. J.; Mooradian, A. D. Inflammation, high-density lipoprotein and cardiovascular dysfunction Curr. Opin Infect Dis. 2011, 24, 265-272
14. Bandeali, S.; Farmer, J. High-density lipoprotein and atherosclerosis: the role of antioxidant activity Curr. Atheroscler. Rep. 2012, 14, 101-107
15. Barter, P. J.; Nicholls, S.; Rye, K. A.; Anantharamaiah, G. M.; Navab, M.; Fogelman, A. M. Antiinflammatory properties of HDL Circ. Res. 2004, 95, 764-772
16. Brunzell, J. D.; Albers, J. J.; Haas, L. B.; Goldberg, A. P.; Agadoa, L.; Sherrard, D. J. Prevalence of serum lipid abnormalities in chronic hemodialysis Metab., Clin. Exp. 1977, 26, 903-910
17. Abrass, C. K. Cellular lipid metabolism and the role of lipids in progressive renal disease Am. J. Nephrol. 2004, 24, 46-53
18. Goldberg, I. J.; Dansky, H. M. Diabetic vascular disease: an experimental objective Arterioscler., Thromb., Vasc. Biol. 2006, 26, 1693-1701
19. Kannel, W. B. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study Am. Heart J. 1985, 110, 1100-1107
20. Vaziri, N. D.; Navab, M.; Fogelman, A. M. HDL metabolism and activity in chronic kidney disease Nat. Rev. Nephrol. 2010, 6, 287-296
21. Asztalos, B. F.; Schaefer, E. J. High-density lipoprotein subpopulations in pathologic conditions Am. J. Cardiol. 2003, 91, 12E-17E
22. Krauss, R. M. Lipids and lipoproteins in patients with type 2 diabetes Diabetes Care 2004, 27, 1496-1504
23. Vaziri, N. D. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease J. Renal Nutr. 2010, 20, S35-S43
24. Holzer, M.; Birner-Gruenberger, R.; Stojakovic, T.; El-Gamal, D.; Binder, V.; Wadsack, C.; Heinemann, A.; Marsche, G. Uremia alters HDL composition and function J. Am. Soc. Nephrol. 2011, 22, 1631-1641
25. Weichhart, T.; Kopecky, C.; Kubicek, M.; Haidinger, M.; Doller, D.; Katholnig, K.; Suarna, C.; Eller, P.; Tolle, M.; Gerner, C.; Zlabinger, G. J.; van der Giet, M.; Horl, W. H.; Stocker, R.; Saemann, M. D. Serum Amyloid A in Uremic HDL Promotes Inflammation J. Am. Soc. Nephrol. 2012, 23, 934-947
26. Vaisar, T.; Pennathur, S.; Green, P. S.; Gharib, S. A.; Hoofnagle, A. N.; Cheung, M. C.; Byun, J.; Vuletic, S.; Kassim, S.; Singh, P.; Chea, H.; Knopp, R. H.; Brunzell, J.; Geary, R.; Chait, A.; Zhao, X. Q.; Elkon, K.; Marcovina, S.; Ridker, P.; Oram, J. F.; Heinecke, J. W. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL J. Clin. Invest. 2007, 117, 746-756
27. Shah, A. S.; Tan, L.; Long, J. L.; Davidson, W. S. Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond J. Lipid Res. 2013, 54, 2575-2585
28. Green, P. S.; Vaisar, T.; Pennathur, S.; Kulstad, J. J.; Moore, A. B.; Marcovina, S.; Brunzell, J.; Knopp, R. H.; Zhao, X. Q.; Heinecke, J. W. Combined statin and niacin therapy remodels the high-density lipoprotein proteome Circulation 2008, 118, 1259-1267
29. Heinecke, J. W. The protein cargo of HDL: implications for vascular wall biology and therapeutics J. Clin Lipidol. 2010, 4, 371-375
30. Link, A. J.; Eng, J.; Schieltz, D. M.; Carmack, E.; Mize, G. J.; Morris, D. R.; Garvik, B. M.; Yates, J. R., 3rd Direct analysis of protein complexes using mass spectrometry Nat. Biotechnol. 1999, 17, 676-682
31. Hoofnagle, A. N.; Becker, J. O.; Oda, M. N.; Cavigiolio, G.; Mayer, P.; Vaisar, T. Multiple-reaction monitoring-mass spectrometric assays can accurately measure the relative protein abundance in complex mixtures Clin. Chem. 2012, 58, 777-781
32. Addona, T. A.; Abbatiello, S. E.; Schilling, B.; Skates, S. J.; Mani, D. R.; Bunk, D. M.; Spiegelman, C. H.; Zimmerman, L. J.; Ham, A. J.; Keshishian, H.; Hall, S. C.; Allen, S.; Blackman, R. K.; Borchers, C. H.; Buck, C.; Cardasis, H. L.; Cusack, M. P.; Dodder, N. G.; Gibson, B. W.; Held, J. M.; Hiltke, T.; Jackson, A.; Johansen, E. B.; Kinsinger, C. R.; Li, J.; Mesri, M.; Neubert, T. A.; Niles, R. K.; Pulsipher, T. C.; Ransohoff, D.; Rodriguez, H.; Rudnick, P. A.; Smith, D.; Tabb, D. L.; Tegeler, T. J.; Variyath, A. M.; Vega-Montoto, L. J.; Wahlander, A.; Waldemarson, S.; Wang, M.; Whiteaker, J. R.; Zhao, L.; Anderson, N. L.; Fisher, S. J.; Liebler, D. C.; Paulovich, A. G.; Regnier, F. E.; Tempst, P.; Carr, S. A. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma Nat. Biotechnol. 2009, 27, 633-641
33. Anderson, L.; Hunter, C. L. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins Mol. Cell. Proteomics 2006, 5, 573-588
34. Anderson, N. L.; Anderson, N. G.; Pearson, T. W.; Borchers, C. H.; Paulovich, A. G.; Patterson, S. D.; Gillette, M.; Aebersold, R.; Carr, S. A. A human proteome detection and quantitation project Mol. Cell Proteomics 2009, 8, 883-886
35. Gerber, S. A.; Rush, J.; Stemman, O.; Kirschner, M. W.; Gygi, S. P. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 6940-6945
36. Ong, S. E.; Mann, M. Mass spectrometry-based proteomics turns quantitative Nat. Chem. Biol. 2005, 1, 252-262
37. Whiteaker, J. R.; Zhao, L.; Anderson, L.; Paulovich, A. G. An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers Mol. Cell. Proteomics 2010, 9, 184-196
38. Mange, A.; Goux, A.; Badiou, S.; Patrier, L.; Canaud, B.; Maudelonde, T.; Cristol, J. P.; Solassol, J. HDL proteome in hemodialysis patients: a quantitative nanoflow liquid chromatography-tandem mass spectrometry approach PLoS One 2012, 7, e34107
39. Himmelfarb, J.; Ikizler, T. A.; Ellis, C.; Wu, P.; Shintani, A.; Dalal, S.; Kaplan, M.; Chonchol, M.; Hakim, R. M. Provision of antioxidant therapy in hemodialysis (PATH): a randomized clinical trial J. Am. Soc. Nephrol. 2014, 25, 623-633
40. Shao, B.; Pennathur, S.; Heinecke, J. W. Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions J. Biol. Chem. 2012, 287, 6375-6386
41. Ryan, R. O.; Forte, T. M.; Oda, M. N. Optimized bacterial expression of human apolipoprotein A-I Protein Expr Purif. 2003, 27, 98-103
42. Yan, W.; Lee, H.; Deutsch, E. W.; Lazaro, C. A.; Tang, W.; Chen, E.; Fausto, N.; Katze, M. G.; Aebersold, R. A dataset of human liver proteins identified by protein profiling via isotope-coded affinity tag (ICAT) and tandem mass spectrometry Mol. Cell. Proteomics 2004, 3, 1039-1041
43. Resing, K. A.; Ahn, N. G. Proteomics strategies for protein identification FEBS Lett.. 2005, 579, 885-9
44. Fu, X.; Gharib, S. A.; Green, P. S.; Aitken, M. L.; Frazer, D. A.; Park, D. R.; Vaisar, T.; Heinecke, J. W. Spectral index for assessment of differential protein expression in shotgun proteomics J. Proteome Res. 2008, 7, 845-854
45. Shao, B.; Tang, C.; Sinha, A.; Mayer, P. S.; Davenport, G. D.; Brot, N.; Oda, M. N.; Zhao, X. Q.; Heinecke, J. W. Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase Circ. Res. 2014, 114, 1733-1742
46. MacLean, B.; Tomazela, D. M.; Shulman, N.; Chambers, M.; Finney, G. L.; Frewen, B.; Kern, R.; Tabb, D. L.; Liebler, D. C.; MacCoss, M. J. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments Bioinformatics. 2010, 26, 966-968
47. de la Llera-Moya, M.; Drazul-Schrader, D.; Asztalos, B. F.; Cuchel, M.; Rader, D. J.; Rothblat, G. H. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages Arterioscler., Thromb., Vasc. Biol. 2010, 30, 796-801
48. Khera, A. V.; Cuchel, M.; de la Llera-Moya, M.; Rodrigues, A.; Burke, M. F.; Jafri, K.; French, B. C.; Phillips, J. A.; Mucksavage, M. L.; Wilensky, R. L.; Mohler, E. R.; Rothblat, G. H.; Rader, D. J. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis N. Engl. J. Med. 2011, 364, 127-135
49. Shao, B.; Tang, C.; Heinecke, J. W.; Oram, J. F. Oxidation of apolipoprotein A-I by myeloperoxidase impairs the initial interactions with ABCA1 required for signaling and cholesterol export J. Lipid Res. 2010, 51, 1849-188
50. Eisen, M. B.; Spellman, P. T.; Brown, P. O.; Botstein, D. Cluster analysis and display of genome-wide expression patterns Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 14863-14868
51. Old, W. M.; Meyer-Arendt, K.; Aveline-Wolf, L.; Pierce, K. G.; Mendoza, A.; Sevinsky, J. R.; Resing, K. A.; Ahn, N. G. Comparison of label-free methods for quantifying human proteins by shotgun proteomics Mol. Cell. Proteomics. 2005, 4, 1487-1502
52. Yamamoto, S.; Yancey, P. G.; Ikizler, T. A.; Jerome, W. G.; Kaseda, R.; Cox, B.; Bian, A.; Shintani, A.; Fogo, A. B.; Linton, M. F.; Fazio, S.; Kon, V. Dysfunctional high-density lipoprotein in patients on chronic hemodialysis J. Am. Coll. Cardiol. 2012, 60, 2372-2379
53. Bhavsar, N. A.; Appel, L. J.; Kusek, J. W.; Contreras, G.; Bakris, G.; Coresh, J.; Astor, B. C. Comparison of measured GFR, serum creatinine, cystatin C, and beta-trace protein to predict ESRD in African Americans with hypertensive CKD Am. J. Kidney Dis. 2011, 58, 886-893
54. Mumtaz, A.; Anees, M.; Bilal, M.; Ibrahim, M. Beta-2 microglobulin levels in hemodialysis patients Saudi J. Kidney Dis. Transplant. 2010, 21, 701-706
55. Volanakis, J. E.; Barnum, S. R.; Giddens, M.; Galla, J. H. Renal filtration and catabolism of complement protein D N. Engl. J. Med. 1985, 312, 395-399
56. Ziegelmeier, M.; Bachmann, A.; Seeger, J.; Lossner, U.; Kratzsch, J.; Bluher, M.; Stumvoll, M.; Fasshauer, M. Serum levels of adipokine retinol-binding protein-4 in relation to renal function Diabetes Care 2007, 30, 2588-2592
57. Mackness, B.; Quarck, R.; Verreth, W.; Mackness, M.; Holvoet, P. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome Arterioscler., Thromb., Vasc. Biol. 2006, 26, 1545-1550
58. Moore, R. E.; Kawashiri, M. A.; Kitajima, K.; Secreto, A.; Millar, J. S.; Pratico, D.; Rader, D. J. Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor Arterioscler., Thromb., Vasc. Biol. 2003, 23, 1914-1920
59. Rubin, E. M.; Krauss, R. M.; Spangler, E. A.; Verstuyft, J. G.; Clift, S. M. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI Nature 1991, 353, 265-267
60. Shih, D. M.; Gu, L.; Xia, Y. R.; Navab, M.; Li, W. F.; Hama, S.; Castellani, L. W.; Furlong, C. E.; Costa, L. G.; Fogelman, A. M.; Lusis, A. J. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis Nature 1998, 394, 284-287
61. Crosby, J.; Peloso, G. M.; Auer, P. L.; Crosslin, D. R.; Stitziel, N. O.; Lange, L. A.; Lu, Y.; Tang, Z. Z.; Zhang, H.; Hindy, G.; Masca, N.; Stirrups, K.; Kanoni, S.; Do, R.; Jun, G.; Hu, Y.; Kang, H. M.; Xue, C.; Goel, A.; Farrall, M.; Duga, S.; Merlini, P. A.; Asselta, R.; Girelli, D.; Olivieri, O.; Martinelli, N.; Yin, W.; Reilly, D.; Speliotes, E.; Fox, C. S.; Hveem, K.; Holmen, O. L.; Nikpay, M.; Farlow, D. N.; Assimes, T. L.; Franceschini, N.; Robinson, J.; North, K. E.; Martin, L. W.; DePristo, M.; Gupta, N.; Escher, S. A.; Jansson, J. H.; Van Zuydam, N.; Palmer, C. N.; Wareham, N.; Koch, W.; Meitinger, T.; Peters, A.; Lieb, W.; Erbel, R.; Konig, I. R.; Kruppa, J.; Degenhardt, F.; Gottesman, O.; Bottinger, E. P.; ODonnell, C. J.; Psaty, B. M.; Ballantyne, C. M.; Abecasis, G.; Ordovas, J. M.; Melander, O.; Watkins, H.; Orho-Melander, M.; Ardissino, D.; Loos, R. J.; McPherson, R.; Willer, C. J.; Erdmann, J.; Hall, A. S.; Samani, N. J.; Deloukas, P.; Schunkert, H.; Wilson, J. G.; Kooperberg, C.; Rich, S. S.; Tracy, R. P.; Lin, D. Y.; Altshuler, D.; Gabriel, S.; Nickerson, D. A.; Jarvik, G. P.; Cupples, L. A.; Reiner, A. P.; Boerwinkle, E.; Kathiresan, S. Loss-of-function mutations in APOC3, triglycerides, and coronary disease N. Engl. J. Med. 2014, 371, 22-31
62. Abrahamson, M.; Dalboge, H.; Olafsson, I.; Carlsen, S.; Grubb, A. Efficient production of native, biologically active human cystatin C by Escherichia coli FEBS Lett. 1988, 236, 14-18
63. Tenstad, O.; Roald, A. B.; Grubb, A.; Aukland, K. Renal handling of radiolabelled human cystatin C in the rat Scand J. Clin. Lab. Invest. 1996, 56, 409-414
64. Winchester, J. F.; Salsberg, J. A.; Levin, N. W. Beta-2 microglobulin in ESRD: an in-depth review Adv. Renal Replacement Ther. 2003, 10, 279-309
65. Liabeuf, S.; Lenglet, A.; Desjardins, L.; Neirynck, N.; Glorieux, G.; Lemke, H. D.; Vanholder, R.; Diouf, M.; Choukroun, G.; Massy, Z. A. Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients Kidney Int. 2012, 82, 1297-1303
66. Pascual, M.; Steiger, G.; Estreicher, J.; Macon, K.; Volanakis, J. E.; Schifferli, J. A. Metabolism of complement factor D in renal failure Kidney Int. 1988, 34, 529-536
67. Jaconi, S.; Rose, K.; Hughes, G. J.; Saurat, J. H.; Siegenthaler, G. Characterization of two post-translationally processed forms of human serum retinol-binding protein: altered ratios in chronic renal failure J. Lipid Res. 1995, 36, 1247-1253
68. Jaconi, S.; Saurat, J. H.; Siegenthaler, G. Analysis of normal and truncated holo- and apo-retinol-binding protein (RBP) in human serum: altered ratios in chronic renal failure Eur. J. Endocrinol. 1996, 134, 576-582
69. Koenig, W.; Twardella, D.; Brenner, H.; Rothenbacher, D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate Clin. Chem. 2005, 51, 321-327
70. Angelidis, C.; Deftereos, S.; Giannopoulos, G.; Anatoliotakis, N.; Bouras, G.; Hatzis, G.; Panagopoulou, V.; Pyrgakis, V.; Cleman, M. W. Cystatin C: an emerging biomarker in cardiovascular disease Curr. Top Med. Chem. 2013, 13, 164-179
71. Taglieri, N.; Koenig, W.; Kaski, J. C. Cystatin C and cardiovascular risk Clin. Chem. 2009, 55, 1932-1943
72. Astor, B. C.; Shafi, T.; Hoogeveen, R. C.; Matsushita, K.; Ballantyne, C. M.; Inker, L. A.; Coresh, J. Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population Am. J. Kidney Dis. 2012, 59, 653-662
73. Shafi, T.; Parekh, R. S.; Jaar, B. G.; Plantinga, L. C.; Oberai, P. C.; Eckfeldt, J. H.; Levey, A. S.; Powe, N. R.; Coresh, J. Serum beta-trace protein and risk of mortality in incident hemodialysis patients Clin. J. Am. Soc. Nephrol. 2012, 7, 1435-1445
74. Cabre, A.; Lazaro, I.; Girona, J.; Manzanares, J.; Marimon, F.; Plana, N.; Heras, M.; Masana, L. Retinol-binding protein 4 as a plasma biomarker of renal dysfunction and cardiovascular disease in type 2 diabetes J. Intern. Med. 2007, 262, 496-503